

Module Innovations to develop nCoVSENSe test for COVID-19

07 April 2020 | News

The startup is planning to deploy the test in a time of 2-3 months after due validation with national agencies

The Department of Science & Technology has funded 'Module Innovations', a Pune based healthcare startup working on point of care diagnostics to build up on its platform technology for rapid diagnosis of diseases to develop a product for detecting COVID 19 with a 10 to 15 minute test.

Using the proven concept from its flagship product USense, Module is now developing nCoVSENSe which is a rapid test device for detection of antibodies that have been generated against the COVID 19 in the human body.

The current confirmatory method of Real-TimeReverse Transcription Polymerase Chain Reaction (RT-PCR) though a gold standard is costly, takes longer time and needs trained manpower. This new rapid test will help manage the problem in a more efficient way at a lesser cost.

"While not being a substitute for the PCR based confirmatory technique, the tests based on the detection of antibodies are being deployed globally for the purposes of rapid mass screenings that take some of the burden off from limited number of PCR machines, and help in the formulation of strategies and decision making, among other things", said Professor Ashutosh Sharma, Secretary, Department of Science & Technology.

The nCoVSENSe test is aimed at detecting the IgG and IgM antibodies generated in the human body upon the onset of viral infection and is targeted against the Spike proteins making it specific for COVID 19.

The startup is planning to deploy the test in a time of 2-3 months after due validation with national agencies. This in future will also help determine people who have recovered and assign them front line jobs. The test could also be used to screen patients and passengers at airports, railway stations, hospitals and many such settings thus safeguarding us for any future outbreak as well.